All In Biotech

Drug Trial Radar · NCT03562637

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 575 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

575

Actual

Start

Dec 5, 2018

Primary completion

Dec 30, 2025

Study completion Dec 30, 2027

Sponsor

Lead sponsor
OBI Pharma, IncIndustry
Sponsor type
Industry
First posted
Jun 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.

Conditions

  • Triple Negative Breast Cancer

Interventions

  • adagloxad simolenin combined with OBI-821Biological

    In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.

  • Globo H IHC AssayDevice

    The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.

  • Standard of care treatmentOther

    Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measuring the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease free survival (IDFS) in the study population.Time frame: 5 years

Locations

128 sites in 13 countries. Site status is shown where the registry gives one.

  • Moores UCSD Cancer Center

    La Jolla, California

  • Kaiser Permanente Medical Center

    San Diego, California

  • UCSF Helen Diller Family Comprehensive Cancer Centre

    San Francisco, California

  • Miami Cancer Institute

    Miami, Florida

  • University of Chicago Medical

    Chicago, Illinois

  • University of Maryland Greenbaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Henry Ford Medical Center

    Detroit, Michigan

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Magee-Womens Hospital of UPMC

    Pittsburgh, Pennsylvania

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Bons Secours St. Francis Medical Oncology Center

    Midlothian, Virginia

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • St Vincent's Hospital Sydney

    Darlinghurst, Australia

  • Gosford Hospital

    Gosford, Australia

  • St John of God Murdoch Hospital

    Murdoch, Australia

  • Eastern Health - Maroondah Hospital

    Ringwood East, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Cancer Care Service, Hervey Bay Hospital

    Urraween, Queensland, Australia

  • Victoria Breast & Oncology Care

    East Melbourne, Victoria, Australia

  • Cabrini Malvern

    Malvern, Victoria, Australia

  • Breast Cancer Research Centre

    Nedlands, Western Australia, Australia

  • Suporte Nutricional e Quimioterapia

    Fortaleza, Ceará, Brazil

  • Centro de Avaliacao de Medicamentos e Especialidades de Pesquisa

    Serra, Espírito Santo, Brazil

  • Hospital Sao Rafael

    Salvador, Estado de Bahia, Brazil

  • Instituto Mario Penna

    Belo Horizonte, Minas Gerais, Brazil

  • Centro de Tratamento Oncologico LTDA - CTO

    Belém, Pará, Brazil

  • Maternidade e Cirurgia Nossa Senhora do Rocio

    Campo Largo, Paraná, Brazil

  • Hospital das Clinicas - Universidade Federal do Parana

    Curitiba, Paraná, Brazil

  • Hospital do Capibaribe

    Recife, Pernambuco, Brazil

  • Real Hospital Portugues de Beneficencia de Pernambuco

    Recife, Pernambuco, Brazil

  • Centro de Pesquisa Vencer & Oncolinca

    Teresina, Piauí, Brazil

  • Hospital de Clinicas de Porto Alegre

    Barretos, Rio Grande do Sul, Brazil

  • Oncosite-Centro de Pesquisa Clinica em Oncologia

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Escola da Universidade Federal de Pelotas

    Pelotas, Rio Grande do Sul, Brazil

  • Irmandade da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Amor Amazonia

    Porto Velho, Rondona, Brazil

  • Centro Oncologico de Roraima

    Boa Vista, Roraima, Brazil

  • Clinica Supera

    Chapecó, Santa Catarina, Brazil

  • Clinica de Neoplasias Litoral - Itajai

    Itajaí, Santa Catarina, Brazil

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.